medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-10-13-18medalphabet-3785Research ArticleСтатьиCOVID‑19 у больных ревматическими заболеваниями: частота и течениеCOVID-19 in patients with rheumatic diseases: frequency and coursehttps://orcid.org/0000-0003-1040-313XКуликовА. Н.KulikovA. N.

Куликов Александр Николаевич, младший научный сотрудник

Москва

Kulikov Alexander N., junior researcher

Moscow

https://orcid.org/0000-0003-4327-6720МуравьеваН. В.MuravyevaN. V.

Муравьева Наталья Валерьевна, к. м. н., старший научный сотрудник

Москва

Muravyova Natalya V., PhD Med, senior researcher

Moscow

https://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

Белов Борис Сергеевич, д. м. н., зав. лабораторией

Москва

Belov Boris S., DM Sci (habil.), head of the laboratory

Moscow

belovbor@yandex.ruФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой»РоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation202421072024110Ревматология в общей врачебной практике (1)1318Copyright © Куликов А.Н., Муравьева Н.В., Белов Б.С., 20242024Куликов А.Н., Муравьева Н.В., Белов Б.С.Kulikov A.N., Muravyeva N.V., Belov B.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3785Цель

Цель. Изучить частоту и тяжесть перенесенного COVID-19 в когорте пациентов с ревматическими заболеваниями (РЗ).

Пациенты и методы

Пациенты и методы. В исследование были отобраны содержащие информацию о наличии или отсутствии новой коронавирусной инфекции (COVID-19) истории болезни 9185 пациентов с иммуновоспалительными РЗ (ИВРЗ) и 491 больного остеоартритом (ОА), наблюдавшихся в ФГБНУ НИИР им. В. А. Насоновой в период с 21 сентября 2021 г. по 28 декабря 2023 г.

Результаты

Результаты. Частота COVID-19 при основных ИВРЗ оказалась значимо выше по сравнению с ОА (р<0,02). Для всех отобранных в исследование нозологий характерно увеличение риска заболеваемости COVID-19 при сопоставлении с ОА в 1,7–3,5 раза. Больным ревматоидным артритом, анкилозирующим спондилитом, болезнью Шегрена, системной склеродермией, псориатическим артритом, системной красной волчанкой, микрокристаллическими артритами, АНЦА-ассоциированными васкулитами и поли/ дерматомиозитами значимо чаще (p<0,009) проводилась терапия COVID-19 по сравнению с контрольной группой. Для пациентов с указанными нозологиями характерно увеличение риска потребности в лечении по поводу COVID-19 в 1,7–6,5 раза в сравнении с ОА. У больных воспалительными заболеваниями суставов, системными заболеваниями соединительной ткани и системными васкулитами необходимость в госпитализации по поводу COVID-19 оказалась значимо выше по сравнению с ОА (р=0,013, p=0,003 и р<0,001 соответственно). Для указанных групп характерно нарастание риска госпитализаций в 3,5–6,8 раза. Помимо этого, для пациентов пожилого и старческого возраста с ИВРЗ отмечен нарастающий риск вероятности назначения терапии, госпитализации и применения генно-инженерных биологических препаратов или таргетных синтетических базисных противовоспалительных препаратов по поводу COVID-19.

Заключение

Заключение. Согласно полученным данным, проблема COVID-19 остается весьма значимой для больных РЗ. Это диктует необходимость продолжения изучения факторов риска неблагоприятных исходов заболевания и вакцинопрофилактики данной инфекционной патологии.

Objectives

Objectives. The aim of the study was to assess frequency and severity of COVID-19 in patients with rheumatic diseases (RD).

Patients and methods

Patients and methods. The study included information on the presence or absence of COVID-19 in the medical history of 9185 patients with immunoinflammatory RD (IIRD) and 491 patients with osteoarthritis (OA) who were observed at the V. A. Nasonova Research Institute of Rheumatology from September 21, 2021 to December 28, 2023.

Results

Results. The incidence of COVID-19 in the analyzed IIRD was significantly higher compared to OA (p<0.02). All IIRD included in the analysis are characterized by an increased risk of COVID-19 incidence when compared with OA by 1.7–3.5 times. Patients with rheumatoid arthritis, ankylosing spondylitis, Sjögren's disease, systemic sclerosis, psoriatic arthritis, systemic lupus erythematosus, microcrystalline arthritis, ANCA- associated vasculitis and poly/dermatomyositis were significantly more likely (p<0.009) to receive COVID-19 therapy compared with the control group. Patients with these diseases are characterized by an increased risk of treatment for COVID-19 by 1.7–6.5 times compared with OA. Also, patients with inflammatory joint diseases (IJD), connective tissue diseases (CTDs) and systemic vasculitis (SV) were hospitalized with COVID-19 more often than patients with OA (p=0.013, p=0.003 and p<0.001, respectively). Patients with IJD, CTDs and SV are characterized by an increased risk of hospitalization with COVID-19 by 3.5–6.8 times compared with OA. In addition, elderly patients with IIRD are characterized by an increasing risk of treatment, hospitalization and use of biologics or targeted synthetic disease-modifying drugs for COVID-19.

Conclusion

Conclusion. According to the data obtained, the problem of COVID-19 remains very significant for patients with RD. This dictates the need to continue studying risk factors for adverse outcomes of the disease and vaccine prevention of this infectious pathology.

иммуновоспалительные ревматические заболеванияCOVID-19эпидемиологиязаболеваемостьвоспалительные заболевания суставовсистемные заболевания соединительной тканисистемные васкулитыimmuno-inflammatory rheumatic diseasesCOVID-19epidemiologymorbidityinflammatory joint diseasesconnective tissue diseasessystemic vasculitisИсследование выполнено в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой» (№ государственного задания 1021051503137–7).ReferencesURL. Вступительное слово Генерального директора ВОЗ на брифинге для СМИ 5 мая 2023 г. Дата доступа: 17.10.2023. URL. Opening remarks by the Director General of WHO at a media briefing on May 5, 2023 Accessed October 17, 2023. https://www.who.int/ru/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-5-may-2023URL. Opening remarks by the Director General of WHO at a media briefing on May 5, 2023 Accessed October 17, 2023. https://www.who.int/ru/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-5-may-2023Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–1242. DOI: 10.1001/jama.2020.2648Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–1242. DOI: 10.1001/jama.2020.2648Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013;52(1):53–61. DOI: 10.1093/rheumatology/kes305Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013;52(1):53–61. DOI: 10.1093/rheumatology/kes305D’Silva KM, Jorge A, Cohen A, et al. COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol. 2021;73(6):914–920. DOI: 10.1002/art.41619D’Silva KM, Jorge A, Cohen A, et al. COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol. 2021;73(6):914–920. DOI: 10.1002/art.41619Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468–1481. DOI: 10.1093/ije/dyaa140Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468–1481. DOI: 10.1093/ije/dyaa140Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. DOI: 10.1038/s41586–020–2521–4Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. DOI: 10.1038/s41586–020–2521–4Wang F, Ma Y, Xu S, et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis. Clin Rheumatol. 2022; 41 (7): 2213–2223. DOI: 10.1007/s10067–022–06087–1Wang F, Ma Y, Xu S, et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis. Clin Rheumatol. 2022; 41 (7): 2213–2223. DOI: 10.1007/s10067–022–06087–1Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021; 73 (3): 374–380. DOI: 10.1002/art.41567Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021; 73 (3): 374–380. DOI: 10.1002/art.41567Бекетова Т. В., Бабак В. В., Супрун М. Д. Течение и исходы COVID-19 у пациентов с АНЦА- ассоциированными системными васкулитами, получающих лечение генно-инженерными биологическими препаратами (ритуксимаб, меполизумаб): итоги первых 8 месяцев пандемии. Научно-практическая ревматология. 2021; 59 (1): 37–46.DOI: 10.47360/1995-4484–2021–37–46Beketova T. V., Babak V. V., Suprun M. D. The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic. Rheumatology Science and Practice. 2021; 59 (1): 37–46 (In Russ.). DOI: 10.47360/1995–4484–2021–37–46Королев М. А., Летягина Е. А., Сизиков А. Е. и др. Иммуновоспалительные ревматические заболевания и COVID-19: анализ клинических исходов по данным регистра пациентов Новосибирской области, получающих терапию генно-инженерными биологическими препаратами. Терапевтический архив. 2022; 94 (5): 636–641. DOI: 10.26442/00403660.2022.05.201502Korolev M. A., Letyagina E. A., Sizikov A. E. et al. Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):636–641 (In Russ.). DOI: 10.26442/00403660.2022.05.201502Мазуров В. И., Беляева И. Б., Саранцева Л. Е. и др. Оценка влияния новой коронавирусной инфекции на клиническое течение ревматических заболеваний в реальной клинической практике. Медицинский алфавит. 2023; (9): 7–16. https://doi.org/10.33667/2078–5631–2023–9–7–16Mazurov V. I., Belyaeva I. B., Sarantseva L. E. et al. Evaluation of impact of new coronavirus infection on clinical course of rheumatic diseases in real clinical practice. Medical alphabet. 2023;(9):7–16. (In Russ.) https://doi.org/10.33667/2078–5631–2023–9–7–16Shin YH, Shin JI, Moon SY. et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021;3(10): e698-e706. DOI: 10.1016/S2665-9913(21)00151-XShin YH, Shin JI, Moon SY. et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021;3(10): e698-e706. DOI: 10.1016/S2665–9913(21)00151-XWang Q, Liu J, Shao R. et al. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851–861. DOI: 10.1007/s00296–021–04803–9Wang Q, Liu J, Shao R. et al. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851–861. DOI: 10.1007/s00296–021–04803–9Conway R, Grimshaw AA, Konig MF., et al. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. Arthritis Rheumatol. 2022;74(5):766–775. DOI: 10.1002/art.42030Conway R, Grimshaw AA, Konig MF., et al. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. Arthritis Rheumatol. 2022;74(5):766–775. DOI: 10.1002/art.42030Shin JI, Kim SE, Lee MH. et al. COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(10):3760–3770. DOI: 10.26355/eurrev_202205_28873Shin JI, Kim SE, Lee MH. et al. COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(10):3760–3770. DOI: 10.26355/eurrev_202205_28873Bournia VK, Fragoulis GE, Mitrou P. et al. Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study. Rheumatology. 2023;62(3):1047–1056. DOI:10.1093/rheumatology/keac422Bournia VK, Fragoulis GE, Mitrou P. et al. Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study. Rheumatology. 2023;62(3):1047–1056. DOI:10.1093/rheumatology/keac422Cordtz R, Lindhardsen J, Soussi BG. et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology. 2021;60(SI): SI59-SI67. DOI: 10.1093/rheumatology/keaa897Cordtz R, Lindhardsen J, Soussi BG. et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology. 2021;60(SI): SI59-SI67. DOI: 10.1093/rheumatology/keaa897Eder L, Croxford R, Drucker AM. et al. COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. J Rheumatol. 2022;49(5):523–530. DOI: 10.3899/jrheum.211012Eder L, Croxford R, Drucker AM. et al. COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. J Rheumatol. 2022;49(5):523–530. DOI: 10.3899/jrheum.211012England BR, Roul P, Yang Y. et al. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis Rheumatol. 2021;73(12):2179–2188. DOI: 10.1002/art.41800England BR, Roul P, Yang Y. et al. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis Rheumatol. 2021;73(12):2179–2188. DOI: 10.1002/art.41800Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021;80(8):1086–1093. DOI: 10.1136/annrheumdis-2021–219845Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021;80(8):1086–1093. DOI: 10.1136/annrheumdis-2021–219845Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1): e044640. DOI: 10.1136/bmjopen-2020–044640Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1): e044640. DOI: 10.1136/bmjopen-2020–044640Gay L, Melenotte C, Lakbar I, et al. Sexual Dimorphism and Gender in Infectious Diseases. Front Immunol. 2021;12:698121. DOI: 10.3389/fimmu.2021.698121Gay L, Melenotte C, Lakbar I, et al. Sexual Dimorphism and Gender in Infectious Diseases. Front Immunol. 2021;12:698121. DOI: 10.3389/fimmu.2021.698121Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г. и др. Международный регистр “Анализ динамики Коморбидных заболеваний у пациенТов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARS-CoV-2)”: анализ 1000 пациентов. Российский Кардиологический Журнал. 2020; 25 (11): 98–107. https://doi.org/10.15829/29/1560–4071–2020–4165Arutyunov G. P., Tarlovskaya E. I., Arutyunov A. G.et al. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of 1,000 patients. Russian Journal of Cardiology. 2020; 25(11):98–107. (In Russ.). https://doi.org/10.15829/29/1560–4071–2020–4165Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–1211. DOI: 10.1038/s41591–020–0962–9Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–1211. DOI: 10.1038/s41591–020–0962–9URL. <Письмо> Роспотребнадзора от 07.04.2020 N 02/6338–2020–15 “О рекомендациях по профилактике коронавирусной инфекции (COVID-19) среди работников” (вместе с «МР 3.1/2.2.0170/3–20. 3.1. Профилактика инфекционных болезней. 2.2. Гигиена труда. Рекомендации… КонсультантПлюс. Дата доступа: 25 декабря 2023. https://www.consultant.ru/document/cons_doc_LAW_349881URL. <Letter> from Rospotrebnadzor dated 04/07/2020 N 02/6338–2020–15 “On recommendations for the prevention of coronavirus infection (COVID-19) among workers» (together with «MR 3.1/2.2.0170/3–20 3.1. Prevention of infectious diseases. 2.2. Occupational health. Recommendations… Consultant Plus. Accessed December 25, 2023 (In Russ.). https://www.consultant.ru/document/cons_doc_LAW_349881URL. Постановление Главного государственного санитарного врача РФ от 16.10.2020 N 31 (ред. от 22.05.2023) «О дополнительных мерах по снижению рисков распространения COVID-19 в период сезонного подъема заболеваемости острыми респираторными вирусными… КонсультантПлюс. Дата доступа: 25 декабря 2023.https://www.consultant.ru/document/cons_doc_LAW_366116URL. Resolution of the Chief State Sanitary Doctor of the Russian Federation dated 10/16/2020 No. 31 (ed. dated 05/22/2023) «On additional measures to reduce the risks of COVID-19 spread during the seasonal increase in the incidence of acute respiratory viral infections… Consultant Plus. Accessed December 25, 2023 (In Russ). https://www.consultant.ru/document/cons_doc_LAW_366116Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol. 2020;32(5):434–440. DOI: 10.1097/BOR.0000000000000725Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol. 2020;32(5):434–440. DOI: 10.1097/BOR.0000000000000725Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. DOI: 10.1136/annrheumdis-2020–217871Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. DOI: 10.1136/annrheumdis-2020–217871Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930–942. DOI: 10.1136/annrheumdis-2020–219498Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930–942. DOI: 10.1136/annrheumdis-2020–219498Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384–391. DOI: 10.1136/annrheumdis-2020–218946Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384–391. DOI: 10.1136/annrheumdis-2020–218946Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. Ther Adv Respir Dis. 2021;15: 1753466621995050. DOI: 10.1177/1753466621995050Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. Ther Adv Respir Dis. 2021;15: 1753466621995050. DOI: 10.1177/1753466621995050Papagoras C, Fragoulis GE, Zioga N, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2022;81(7):1013–1016. DOI: 10.1136/annrheumdis-2021–221539Papagoras C, Fragoulis GE, Zioga N, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2022;81(7):1013–1016. DOI: 10.1136/annrheumdis-2021–221539Мазуров В. И., Насонов Е. Л., Лила А. М. и др. Проблемы вакцинации от новой коронавирусной инфекции при ревматических болезнях. Вестник Северо-Западного государственного медицинского университета им И. И. Мечникова. 2022;14(3):39–51. DOI: https://doi.org/10.17816/mechnikov108970.Mazurov V. I., Nasonov E. L., Lila A. M. et al. Problems associated with new coronavirus infection vaccination in patients with rheumatic diseases. Herald of North-Western State Medical University named after I. I. Mechnikov. 2022;14(3):39–51 (In Russ.). DOI: https://doi.org/10.17816/mechnikov108970.URL. Итоговое заявление о работе пятнадцатого совещания Комитета Международных медико-санитарных правил (2005 г.) по чрезвычайной ситуации в связи с пандемией коронавирусной инфекции (COVID-19). 05.05.2023. Дата доступа 26.12.2023. https://www.who.int/ru/news/item/05–05–2023-statement-on-the-fifteenth-meeting-of-the-international-health-regula-tions-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.URL. Final statement on the work of the fifteenth meeting of the International Health Regulations Committee (2005) on the emergency situation in connection with the coronavirus pandemic (COVID-19). 05.05.2023. Accessed December 26, 2023. https://www.who.int/ru/news/item/05–05–2023-statement-on-the-fifteenth-meeting-of-the-international-health-regula-tions-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.Насонов Е. Л., Лила А. М., Мазуров В. И. и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021; 59 (3): 239–254. DOI: 10.47360/1995–4484–2021–239–254Nasonov E. L., Lila A. M., Mazurov V. I. et al. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Rheumatology Science and Practice. 2021;59(3):239–254. (In Russ.). DOI: 10.47360/1995–4484–2021–239–254

The authors declare that there are no conflicts of interest present.